Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24610741 | 0.87 | ALDH1A1 (0.58) | ALDH1A1TSHRKMT2AMEN1TDP1 | |
| SCHEMBL14814315 | 0.77 | BTK (0.49) | ALDH1A1TSHRKMT2AMEN1TDP1 | |
| SCHEMBL14749827 | 0.77 | BTK (0.49) | ALDH1A1TSHRKMT2AMEN1TDP1 | |
| SCHEMBL29093223 | 0.77 | BTK (0.49) | ALDH1A1TSHRKMT2AMEN1TDP1 | |
| SCHEMBL29092737 | 0.77 | BTK (0.49) | ALDH1A1TSHRKMT2AMEN1TDP1 | |
| SCHEMBL21518920 | 0.77 | BTK (0.49) | ALDH1A1TSHRKMT2AMEN1TDP1 | |
| SCHEMBL22504168 | 0.77 | BTK (0.49) | ALDH1A1TSHRKMT2AMEN1TDP1 | |
| SCHEMBL21518921 | 0.77 | BTK (0.49) | ALDH1A1TSHRKMT2AMEN1TDP1 | |
| SCHEMBL14814362 | 0.77 | BTK (0.49) | ALDH1A1TSHRKMT2AMEN1TDP1 | |
| SCHEMBL23716898 | 0.74 | SMN1; SMN2 (0.67) | ALDH1A1TSHRKMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014910-B2 | Methyllactam ring compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-20190352284-A1 | METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014910-B2 | Methyllactam ring compound and pharmaceutical use thereof | SLC5A1, SLC5A2, SLC5A6 | ALDH1A1 431/4885TSHR 4110/4885KMT2A 236/4885 |
| US-20190352284-A1 | METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, SLC5A6 | ALDH1A1 431/4885TSHR 4110/4885KMT2A 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.